A B S T R A C T A rabbit model of pneumococcal meningitis was used to examine the importance of bactericidal vs. bacteriostatic antimicrobial agents in the therapy of meningitis. 112 animals were infected with one of two strains of type III Streptococcus pneumoniae. Both strains were exquisitely sensitive to ampicillin, minimum inhibitory concentration (MIC)/ minimum bactericidal concentration (MBC) <0.125 ug/ml. The activity of chloramphenicol against the two strains varied: strain1-MIC 2 ug/ml, MBC 16 /Ag/ml; strain2-MIC 1 ,g/ml, MBC 2 ,g/ml. Animals were treated with either ampicillin or chloramphenicol in dosages that achieved a peak bactericidal effect in cerebrospinal fluid (CSF) for ampicillin against both strains. Two different dosages were used for chloramphenicol. The first dosage achieved a peak CSF concentration of 4.4±1.1 gg/ml that produced a bacteriostatic effect against strainI and bactericidal effect against strain2. The second dosage achieved a bactericidal effect against both strains (mean peak CSF concentration 30.0 Ag/ml). All 
A B S T R A C T A rabbit model of pneumococcal meningitis was used to examine the importance of bactericidal vs. bacteriostatic antimicrobial agents in the therapy of meningitis. 112 animals were infected with one of two strains of type III Streptococcus pneumoniae. Both strains were exquisitely sensitive to ampicillin, minimum inhibitory concentration (MIC)/ minimum bactericidal concentration (MBC) <0.125 ug/ml. The activity of chloramphenicol against the two strains varied: strain1-MIC 2 ug/ml, MBC 16 /Ag/ml; strain2-MIC 1 ,g/ml, MBC 2 ,g/ml. Animals were treated with either ampicillin or chloramphenicol in dosages that achieved a peak bactericidal effect in cerebrospinal fluid (CSF) for ampicillin against both strains. Two different dosages were used for chloramphenicol. The first dosage achieved a peak CSF concentration of 4.4±1.1 gg/ml that produced a bacteriostatic effect against strainI and bactericidal effect against strain2. The second dosage achieved a bactericidal effect against both strains (mean peak CSF concentration 30 .0 Ag/ml). All animals were treated intramuscularly three times a day for 5 d. CSF was sampled daily and 3 d after discontinuation of therapy for quantitative bacterial cultures. Results demonstrate INTRODUCTION Despite the introduction of newer antibiotics (e.g., ampicillin or chloramphenicol), the mortality rate in pneumococcal meningitis has not improved since penicillin was introduced for therapy more than 30 yr ago. In six large series of studies comprising 439 patients over the last three decades, recently reviewed (1), the mortality rate of pneumococcal meningitis ranged from 17 to 59% (mean of 28%), identical to the overall case fatality rate for cases treated in the United States and reported to the Centers for Disease Control in 1978 (2) . Although certain poor prognostic factors, especially coma (3) , may indicate an irreversible process at admission in many cases, the choice and method of administration of antibiotics also is of critical importance.
Several lines of evidence indicate that bacterial meningitis represents an infection in an area of impaired host resistance. Bacterial concentrations within the cerebrospinal fluid (CSF)' reach enormous population densities within 72 h of the onset of the illness, e.g., 2107 colony-forming units (cfu)/ml of CSF in many cases (4, 5) . The polymorphonuclear leukocytes seem to contribute little defense in such cases. Surface phagocytosis, an important factor in promoting phagocytosis of unopsonized pneumococci within alveoli in pneumonia (6) , is poor in the fluid medium of the CSF. Since specific antibody and functional complement components are absent from CSF early in the course of infection (7) (8) (9) (10) , efficient phagocytosis of the encapsulated pneumococci may not occur. Thus, bacterial multiplication continues unimpeded within the CSF before the leukocytes appear, despite the chemoattractiveness of purulent CSF (11, 12) . Cases of pneumococcal meningitis with a turbid CSF due solely to bacteria (e.g., low leukocyte counts) are well recognized clinically, and generally are fatal. A high CSF bacterial concentration with a low leukocyte count before therapy is a poor prognostic sign in both experimental meningitis (13) and man (4, 5, 14) .
Thus, as in other infections where host defenses are impaired, like bacterial endocarditis or bacteremia in leukopenic patients (15, 16) , one would expect that optimal therapy of bacterial meningitis would require achieving a bactericidal effect at the site of infection. Several experimental studies suggest that this is the case. CSF aminoglycoside levels greatly exceeding the minimum bactericidal concentration (MBC) were necessary for effective reduction in bacterial titers in vivo in experimental meningitis induced by gram-negative bacilli (17) , where chloramphenicol, a static agent, was without effect (18) . In another study, a bactericidal, but not a bacteriostatic, combination regimen was effective in reducing numbers of viable bacteria in experimental Escherichia coli meningitis (19) . Comparable information for pneumococcal meningitis in either animals or man is not available, and the requirement for bactericidal therapy in any form of meningitis remains unproven.
Because it is impossible to study these principles in man, experimental models of infection must be utilized. This study was specifically designed to determine the importance of achieving a bactericidal effect vs. a bacteriostatic effect in CSF on the cure of experimental pneumococcal meningitis. We utilized two drugs (ampicillin and chloramphenicol), in different dosages, and two strains of pneumococci with different susceptibilities to approach this problem.
I Abbreviations used in this paper: cfu, colony-forming units; CSF, cerebrospinal fluid; MBC, minimum bactericidal concentration; MIC, minimum inhibitory concentration.
METHODS

In vitro studies
The minimum inhibitory concentrations (MIC) In vivo studies Rabbit model. New Zealand White rabbits (2-3 kg) were prepared, with minor modifications, as previously described (20, 21) . A dental acrylic helmet was attached to the animal's skull to facilitate rigid immobilization within a stereotaxic frame. A Quincke spinal needle, 25 gauge by 3.5 in (-9 cm), was introduced percutaneously and atraumatically into the cisterna magna by a geared electrode introducer. These needles were used for both initial bacterial inoculation and for CSF sampling during the treatment course.
Preparation of inocula. Two strains of S. pneumoniae, type III, were grown overnight at 37°C in 10% CO2 in BHIB plus 5% defibrinated sheep blood and centrifuged (400 g for 5 min) to remove erythrocytes. The organisms were then recentrifuged (3,000 g for 15 min) and washed in 0.9% NaCl twice before suspension in 2 ml 0.9% NaCl at a final concentration of 107 cfu/ml.
Production of meningitis. After withdrawal of clear CSF (0.3 ml) the bacterial inocula (in 0.2 ml) were slowly injected into the cisterna magna at a final concentration of =2 X 107 cfu/0.2 ml. The postinoculation interval before the initiation of therapy was 16-18 h. All animals had meningitis as manifest by fever (>40°C), neurologic signs (principally lethargy and/or opisthotonus), a CSF pleocytosis (5 X 102 to >2.5 X 103 leukocytes/mm3, .95% polymorphonuclear leuko-cytes) and CSF bacterial concentrations of loglo 4.0 to >8.0 cfu/ml. All untreated control animals died within 96 h of infection.
Experimental design
Treatment of 112 animals was begun 16 h after inoculation with one of three antibiotic dosages: ampicillin (250 mg), chloramphenicol (375 or 1,000 mg). All drugs were given intramuscularly three times daily, and the formulations used were sterile ampicillin sodium (Polycillin-N, Bristol-Myers Products, New York) and sterile chloramphenicol sodium succinate (Chloromycetin, Parke-Davis, division of WarnerLambert Company, Morris Plains, NJ). Daily samples of serum (3 ml venous blood) and CSF (0.25 ml) were obtained during the 5-d treatment period. After 5 d of therapy all antibiotics were stopped, and the CSF was sampled 3 d later (8 d after inoculation) to determine the incidence of relapses, if any. In addition, serum (1.0 ml) and CSF (0.15 ml) samples were obtained frequently after the morning dose on days 2 and 3 to define drug pharmacokinetics and delivery into the CSF. The times of sampling (in hours after the dose) were 0.5, 1, 1.5, 2, 3, 4, 6, and 8.
Two strains of S. pneumonuse type III were used in these studies to assess the influence of CSF bactericidal activity on outcome. The MBC of chloramphenicol for the first strain (strain1) was 16 ,g/ml, which was above the mean CSF concentration of 4 gg/ml attained on "low"-dose chloramphenicol therapy (375 mg t.i.d.) but below the CSF chloramphenicol concentration of 30 ug/ml achieved when the "high"-dose chloramphenicol (1,000 mg t.i.d.) was used. The second strain (strain2) had a MBC of 2 ug/ml, which was below the mean CSF chloramphenicol concentrations achieved with either regimen.
The influence of the antibiotic regimen on rate of decline in CSF bacterial titers over the first 24 Antibiotic assays. Antibiotic concentrations were determined by agar-well diffusion techniques. Bacillus subtilis spore suspension (0.9 ml, Difco Laboratories) was added to 1,000 ml antibiotic medium No 11 (Difco Laboratories) for determination of ampicillin levels. The initial chloramphenicol assays used a 2.5-ml suspension of Sarcina lutea (ATCC 9341) incorporated into antibiotic medium No 1 (Difco Laboratories). This suspension gave a transmission of 21% at 580 nm. Most (>90%) chloramphenicol bioassays, however, were performed against a marine bacterium, Beneckea natrigens in 1.5% salt agar, because this technique is simpler, more rapid, highly reproducible, and requires smaller volumes of sample (22) . The lower limit of detectability of this bioassay was only _2 gg/ml; therefore, all samples with no zone of inhibition were repeated with a highly sensitive enzymatic assay (23) Mg/ml.
In the dynamic bactericidal studies (Fig. 1) , ampicillin sterilized (e.g., <101 cfu/ml due to sensitivity of the assay) the broth culture of both test strains of S. pneumoniae within 12 h, while control cultures increased from -105 cfu/ml to -108 cfu/ml. The ampicillin concentration used (2.5 sg/ml) was similar to concentrations achievable in infected CSF and 20 times higher than the MBC. In contrast, chloramphenicol, at the concentration tested (10 ,ug/ml) was rapidly bactericidal for strain2 only (Fig. lb) . This concentration exceeded the MBC by fivefold. Chloramphenicol (at 10 gg/ml) produced a bacteriostatic effect against strain1. The concentration used was approximately one-half the MBC (16 gg/ml) of the organism (Fig. la) FIGURE 1 (a) Mean±SD loglo cfu/ml S. pneumoniae (strain,) during incubation in vitro with no drug-controls (@ *), ampicillin (2.5 jig/ml; 0 0), and chloramphenicol (10 jug/ ml; *---). (b) Mean±SD loglo cfu/ml S. pneumoniae (strain2) during incubation in vitro with no drug-controls (0-0), ampicillin (2.5 jg/ml; 0 0), and chloramphenicol (10 Ag/ml; --A-).
ampicillin concentration also occurred at 30 min after injection and was 10-15% of the concurrent serum concentration in each animal. The serum and CSF chloramphenicol concentrations were dependent on dose (Fig. 3) . The strains, the mean peak levels were 126 Ag/ml in the serum and 30,ug/ml in the CSF. The T1/2 in CSF was longer for chloramphenicol than for ampicillin, and concentrations were detectable (21 ,ug/ml) ,gg/ml; chloramphenicol MBC = 16 jig/ml), the lowdose chloramphenicol regimen was less effective than ampicillin in reducing CSF pneumococcal concentrations after 24 h (e.g., three doses) of treatment (P < 0.001) (Fig. 4a, Table I ). The high-dose chloramphenicol group (with mean CSF drug concentrations two times the MBC) reduced the mean CSF pneumococcal concentrations -5.5 logs after 24 (11) 100 (8) The number in parentheses represents the number of animals used in each computation.
chloramphenicol MBC = 2 Atg/ml) was used as the infecting organism, the results were different (Fig. 4b , Table I (Table  II) . Cure, defined as disease-free survival to day 8 (3 d after treatment was terminated) with a documented sterile CSF, was achieved in only 3 of 18 animals infected with the strain that was tolerant to chloramphenicol (strain,) and treated with the low-dose chloramphenicol regimen compared with 17 of 22 receiving ampicillin alone (P = 0.022). The regimen of highdose chloramphenicol produced cure rates not significantly different from ampicillin alone. 70-80% of an- imals infected with the highly chloramphenicol-sensitive strain of S. pneumoniae (strain2) were cured with ampicillin or low-dose chloramphenicol and there were no differences between treatment groups. Relapses (defined as a rise in CSF pneumococcal concentration between the end of therapy, day 5 and day 8) were rarely observed except in the low-dose chloramphenicol group in animals inoculated with strain1. In this group, six of nine surviving animals on day 5 demonstrated a relapse vs. one of eight in the high-dose chloramphenicol group (P < 0.05). No relapses were observed in the animals infected with strain1 and treated with ampicillin (Table II) although 5/22 died during treatment. Only 2 of 17 animals relapsed when inoculated with strain2, and all treatment regimens were equivalent when this parameter was examined (P > 0.5).
DISCUSSION
This study examines the critical importance of bactericidal vs. bacteriostatic antibiotic therapy of experimental bacterial meningitis. Two antimicrobial agents, ampicillin and chloramphenicol, were used as probes to explore this question. Under the condition of the present study, one of these agents, ampicillin, always achieved bactericidal activity within the infected CSF in vivo in experimental pneumococcal meningitis, whereas the other agent, chloramphenicol, achieved bactericidal activity in only one model of infection. Dosages were chosen and two pneumococcal strains were selected to test the hypothesis that bactericidal activity at the site of infection (e.g., CSF) was necessary for a successful outcome. The results strongly support the conclusion that when CSF antibiotic levels exceeded the MBC for the test strain, the results of therapy were significantly better by all parameters than the results achieved with regimens that did not attain CSF antibiotic concentrations above this level. The need for bactericidal antibiotics for optimal therapy of bacterial meningitis is suggested by several lines of evidence: (a) the disease represents an infection in an area of impaired host resistance (7-9, 13, 24) , and may, like bacterial endocarditis and bacteremia in the neutropenic host (15, 16) , require bactericidal antibiotics for cure; and (b) most studies of experimental meningitis in animals suggest that CSF antibiotic concentrations must exceed the MBC of the test strain by severalfold to achieve rapid bacterial killing in vivo (17) (18) (19) (25) (26) (27) (28) .
Bacterial concentrations in CSF achieve huge population densities early in the disease course (4, 5) . The densities (often 2107 cfu/ml CSF) are similar to those noted within cardiac vegetations in experimental animals and man with endocarditis (29, 30) , a disease that requires bactericidal antibiotic therapy for cure. The CSF pneumococcal concentrations in the present experiments, before therapy, were in the range of log1o 4.0->8.0 cfu/ml, similar to previously reported studies with experimental meningitis (27) . In addition, concentrations regularly exceeded 108 cfu/ml CSF at the time of death in untreated animals, as noted in other studies (12, 27, 28, (31) (32) (33) (34) . These bacterial concentrations likely reflect inefficient host defense mechanisms at the site of infection. Leukocyte phagocytosis of unopsonized encapsulated organisms such as pneumococci is ineffective in the fluid medium of the CSF (6), but some resistance to infection must occur since the disease is more rapidly fatal in animals when CSF leukocyte concentrations are low (13, 35) . Despite the detection of immunoglobulins in the CSF of patients with meningitis or encephalitis (7, 36, 37) , the functional activity of these components, in concert with complement, is very poor at the site of infection. Purulent CSF appears to lack significant bactericidal or opsonic activity (7, 8, 10) . Complement deficiencies predispose to recurrent bouts of meningitis (38, 39) , and complement components are essential for the control of experimental pneumococcal infections in noncentral nervous system locales as well (40, 41) . These relative deficiencies permit the extracellular pneumococci to continue multiplying within the CSF and strongly suggest the need for bactericidal antibiotics for cure. Two other host defense mechanisms are also potentially important. Bacteria grow slowly in CSF when compared with broth (42)2, which may interfere with the action of certain antibiotics, such as the beta lactams, maximally effective during rapid bacterial growth. In addition, the normal clearance mechanism of the CSF is operative early during experimental meningitis (43) , but resistance to CSF outflow increases during experimental meningitis in rabbits (44) (25, 26) . These studies were of short duration; the experiments in this paper are confirmatory and extend these observations to long term (5 d) therapy and ultimate outcome (e.g., cure). Our studies in rabbits, thus, provided the logical explanation for the dramatic differences in cure rates of pneumococcal meningitis reported by Lepper and Dowling (47) in 1951. They found a 79% cure rate in patients receiving penicillin G alone (a bactericidal drug) but only a 30% cure rate in patients receiving penicillin plus chlortetracycline (a drug that antagonized the bactericidal action of penicillin resulting in a static effect). A recent report by Cherubin et al. (48) also suggests that patients who received chloramphenicol for meningitis caused by gram-negative bacilli had a higher failure rate than those treated with aminoglycosides alone (49) . Chloramphenicol is a static drug against most gram-negative bacilli and, when used in combination with aminoglycosides, may reduce or eliminate the bactericidal activity of the latter drug (18) . Thus, these carefully controlled studies demonstrate the principle that optimal therapy of experimental bacterial meningitis in vivo requires the usage of bactericidal, not bacteriostatic antibiotics. Although we have not performed laborious 5-d treatment courses in other types of experimental bacterial meningitis, we believe the results with pneumococcal meningitis may also be applicable to other infectious etiologies. The evidence of this study suggests that bacterial meningitis, like endocarditis or septicemia in a neutropenic host, demands bactericidal antibiotics for optimal therapy. The few clinical studies reported suggest this concept. Certainly, antibiotics alone will not always determine the clinical course, but this principle appears valid and should be a rational goal when examining new antimicrobial agents for treatment of bacterial meningitis (49) .
